Eagle Asset Management Inc. Has $60.61 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Eagle Asset Management Inc. lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 56.1% during the third quarter, Holdings Channel.com reports. The firm owned 119,965 shares of the company’s stock after selling 153,314 shares during the period. Eagle Asset Management Inc.’s holdings in IDEXX Laboratories were worth $60,609,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. American Century Companies Inc. grew its holdings in shares of IDEXX Laboratories by 46.0% during the second quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock valued at $274,179,000 after buying an additional 177,226 shares during the last quarter. International Assets Investment Management LLC raised its stake in shares of IDEXX Laboratories by 52,746.0% in the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after purchasing an additional 527,460 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of IDEXX Laboratories by 13.1% in the second quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company’s stock worth $249,855,000 after purchasing an additional 59,519 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of IDEXX Laboratories by 4.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 406,086 shares of the company’s stock valued at $205,163,000 after purchasing an additional 15,521 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its position in shares of IDEXX Laboratories by 696.0% during the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company’s stock valued at $171,891,000 after buying an additional 308,493 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 0.2 %

IDEXX Laboratories stock opened at $419.37 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $34.34 billion, a P/E ratio of 40.44, a P/E/G ratio of 3.63 and a beta of 1.36. The firm has a 50 day moving average price of $462.53 and a 200-day moving average price of $481.11. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the business posted $2.53 earnings per share. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Piper Sandler reissued a “neutral” rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Stifel Nicolaus lowered their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. BTIG Research began coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. Barclays dropped their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. cut their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $552.38.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.